A

Adcock Ingram Holdings Ltd
JSE:AIP

Watchlist Manager
Adcock Ingram Holdings Ltd
JSE:AIP
Watchlist
Price: 7 480.0003 Zac Market Closed
Market Cap: 12.1B Zac

Relative Value

There is not enough data to reliably calculate the relative value of AIP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AIP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

AIP Competitors Multiples
Adcock Ingram Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ZA
Adcock Ingram Holdings Ltd
JSE:AIP
12.1B Zac 0 0 0 0
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 56 37.5 40.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
528.9B USD 5.7 21 17.2 22.3
CH
Roche Holding AG
SIX:ROG
275.5B CHF 4.5 29.2 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP 0 0.3 0 0
CH
Novartis AG
SIX:NOVN
220.8B CHF 5 19.4 15.3 19.8
US
Merck & Co Inc
NYSE:MRK
272B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.6 17 11.8 13.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
148.4B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average P/E: 21.5
Not Available
6%
N/A
US
Eli Lilly and Co
NYSE:LLY
56
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
17
3%
5.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average EV/EBITDA: 45.7
Not Available
5%
N/A
US
Eli Lilly and Co
NYSE:LLY
37.5
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.3
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
1%
11.8
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ZA
A
Adcock Ingram Holdings Ltd
JSE:AIP
Average EV/EBIT: 100
Not Available
4%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
0
23%
0
CH
Novartis AG
SIX:NOVN
19.8
12%
1.6
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5